Molecular structure of R935788 (Fostamatinib disodium, R788), CAS Number: 1025687-58-4
R935788 (Fostamatinib disodium, R788) (CAS 1025687-58-4)
Alternate Names:
R 788 sodium; FosD
Application:
R935788 (Fostamatinib disodium, R788) is an inhibitor to spleenic kinase-mediated IgG Fc receptor signaling
CAS Number:
1025687-58-4
Purity:
≥98%
Molecular Weight:
624.42
Molecular Formula:
C23H24FN6O9P•2Na
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
R935788 (Fostamatinib disodium, R788) is an important spleen tyrosine kinase (Syk) inhibitor, showing efficacy against kinase-mediated IgG Fc gamma receptor signaling. R935788 (Fostamatinib disodium, R788) inhibits the activation of mast cells, macrophages, and B-cells and related inflammatory responses and tissue damage. In one study, inhibition of BCR signaling with R788 affected the growth of certain leukemia cell lines. These leukemia cells express stereotyped BCRs that react with auto-antigens exposed on the surface of senescent or apoptotic cells, suggesting that they are antigen driven.
R935788 (Fostamatinib disodium, R788) (CAS 1025687-58-4) References
- A spleen tyrosine kinase inhibitor reduces the severity of established glomerulonephritis. | Smith, J., et al. 2010. J Am Soc Nephrol. 21: 231-6. PMID: 19959716
- The Syk kinase as a therapeutic target in leukemia and lymphoma. | Efremov, DG. and Laurenti, L. 2011. Expert Opin Investig Drugs. 20: 623-36. PMID: 21438742
- The oral spleen tyrosine kinase inhibitor fostamatinib attenuates inflammation and atherogenesis in low-density lipoprotein receptor-deficient mice. | Hilgendorf, I., et al. 2011. Arterioscler Thromb Vasc Biol. 31: 1991-9. PMID: 21700926
- Syk inhibition with fostamatinib leads to transitional B lymphocyte depletion. | Barr, PM., et al. 2012. Clin Immunol. 142: 237-42. PMID: 22284392
- The status of fostamatinib in the treatment of rheumatoid arthritis. | Morales-Torres, J. 2012. Expert Rev Clin Immunol. 8: 609-15. PMID: 23078058
- Correlation and cluster analysis of immunomodulatory drugs based on cytokine profiles. | Wallner, FK., et al. 2018. Pharmacol Res. 128: 244-251. PMID: 29079427
- Discovery of novel Syk/PDGFR-α/c-Kit inhibitors as multi-targeting drugs to treat rheumatoid arthritis. | Li, X., et al. 2018. Bioorg Med Chem. 26: 4375-4381. PMID: 30078608
- Fostamatinib for the treatment of chronic immune thrombocytopenia. | Connell, NT. and Berliner, N. 2019. Blood. 133: 2027-2030. PMID: 30803989
- TOSO interacts with SYK and enhances BCR pathway activation in chronic lymphocytic leukemia. | Zhang, YR., et al. 2020. Chin Med J (Engl). 133: 2090-2097. PMID: 32784334
- Fostamatinib: a review of its clinical efficacy and safety in the management of chronic adult immune thrombocytopenia. | Newland, A. and McDonald, V. 2020. Immunotherapy. 12: 1325-1340. PMID: 33023353
- Safety and efficacy of newer biologics DMARDs in the management of rheumatoid arthritis: A systematic review. | Zago, BA., et al. 2020. Osteoarthr Cartil Open. 2: 100116. PMID: 36474893
- Heterogeneity of Patient-Derived Acute Myeloid Leukemia Cells Subjected to SYK In Vitro Inhibition. | Brattås, MK., et al. 2022. Int J Mol Sci. 23: PMID: 36499034
Inhibitor of:
Enzyme, and Syk.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
R935788 (Fostamatinib disodium, R788), 5 mg | sc-364598 | 5 mg | $260.00 | |||
R935788 (Fostamatinib disodium, R788), 50 mg | sc-364598A | 50 mg | $1484.00 |